RightFit Trial Directory

Sickle Cell Disease clinical trials in Washington D.C., DC

15 recruiting sickle cell disease studies with a site in Washington D.C., DC.

All trials in Washington D.C., DC · All Sickle Cell Disease trials

RecruitingPhase 3NCT06439082

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sponsor: Novartis Pharmaceuticals

Washington D.C., DC · +16 more sites

RecruitingPhase 3NCT06975865

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Sponsor: Sanofi

Washington D.C., DC · +20 more sites

RecruitingPhase 2NCT06699849

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Sponsor: CSL Behring

Washington D.C., DC · +19 more sites

RecruitingPhase 3NCT06609226

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Sponsor: Novo Nordisk A/S

Washington D.C., DC · +38 more sites

RecruitingPhase 3NCT06612268

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Sponsor: Novo Nordisk A/S

Washington D.C., DC · +48 more sites

RecruitingPhase not listedNCT00081523

Natural History of Sickle Cell Disease

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Washington D.C., DC · +2 more sites

RecruitingPhase not listedNCT04398628

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Sponsor: American Thrombosis and Hemostasis Network

Washington D.C., DC · +74 more sites

RecruitingPhase 4NCT04657822

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Sponsor: Novartis Pharmaceuticals

Washington D.C., DC · +6 more sites

RecruitingPhase not listedNCT06941389

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Sponsor: University of Rochester

Washington D.C., DC · +30 more sites

RecruitingPhase 2NCT06635902

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

Sponsor: Suvankar Majumdar

Washington D.C., DC

RecruitingPhase 2NCT03587272

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

Sponsor: Robert Nickel

Washington D.C., DC · +4 more sites

RecruitingPhase 2NCT06358638

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

Sponsor: Children's National Research Institute

Washington D.C., DC

RecruitingNot applicableNCT06770010

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

Sponsor: Children's National Research Institute

Washington D.C., DC

RecruitingNot applicableNCT05099874

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Sponsor: Children's National Research Institute

Washington D.C., DC

Not yet recruitingPhase 3NCT06989567

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Sponsor: Asklepion Pharmaceuticals, LLC

Washington D.C., DC · +5 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.